Transcode Therapeutics (RNAZ) Assets Average (2021 - 2026)

Transcode Therapeutics (RNAZ) has reported Assets Average for 6 consecutive years, with $154.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 1335.99% year-over-year to $154.1 million; the trailing twelve-month figure through Jun 2026 stood at $154.1 million (up 1335.99% YoY), and the FY2025 full-year result was $84.8 million, up 1261.44% from the prior year.
• Assets Average declined to $154.1 million in Q2 2026 per RNAZ's latest filing, from $159.8 million in the prior quarter.
• Across five years, Assets Average topped out at $159.8 million in Q1 2026 and bottomed at $4.4 million in Q3 2024.
• Historically, Assets Average has averaged $29.8 million across 5 years, with a median of $8.9 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Assets Average sank 68.46% in 2023, then soared 1459.69% in 2026.
• Over 5 years, Assets Average stood at $9.8 million in 2022, then decreased by 21.46% to $7.7 million in 2023, then dropped by 27.06% to $5.6 million in 2024, then soared by 1392.58% to $83.8 million in 2025, then jumped by 83.85% to $154.1 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $154.1 million, $159.8 million, and $83.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.